Galenica Claims Number-One Spot In Swiss Consumer Health Market
Executive Summary
Galenica's Verfora took the lead in the Swiss consumer health market for the first time ever in 2018, ahead of its multinational rivals. But the firm is not stopping there. It has acquired a stake in local complementary medicines player Spapyros to take a slice of the poplar homeopathy market.
You may also be interested in...
Galenica Expands Swiss OTC Offering Through Hedoga Acquisition
Galenica has reinforced its position as the leading player in the Swiss OTC market through the acquisition of Hedoga Group,
Dermocosmetics Push Yields Results For Switzerland's Galenica
Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.
Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy
Swiss medicines authority, Swissmedic, rules that hundreds of non-prescription medicines are safe to be purchased outside pharmacy, following the completion of its review of the country's medicines classification system.